Benjamin L. Oakes
Co-founder, President, and Chief Executive Officer at Scribe Therapeutics
Meet Benjamin L. Oakes
Oakes has contributed to over 25 publications and patent applications across synthetic biology, molecular engineering, CRISPR, and zinc finger-based genetic modification. He received a PhD in Molecular and Cellular Biology from the University of California, Berkeley, in 2017, where he worked in the Doudna Lab and Savage Lab developing CRISPR-Cas9 molecules with enhanced characteristics. Scribe Therapeutics was spun out of the Doudna lab in 2018.